Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Destiny-Gastric05: Trastuzumab Deruxtecan in HER2-Positive Gastric or GEJ Cancer
NCT06731478Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2025
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan in gastric cancer (GC) and gastroesophageal junction cancer (4 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Progression Free Survival up to 59 months. Started Feb 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT06731478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06731478.